3,5-Difluorotyrosine is a synthetic analog of the amino acid tyrosine, with fluorine atoms at the 3 and 5 positions. It has been investigated as a potential therapeutic agent due to its ability to act as a substrate for enzymes involved in dopamine biosynthesis. 3,5-Difluorotyrosine has been shown to inhibit tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, leading to a reduction in dopamine levels in the brain. This property has led to its exploration as a potential treatment for neuropsychiatric disorders, particularly those characterized by dopamine dysregulation, such as Parkinson's disease, schizophrenia, and drug addiction. Research on 3,5-difluorotyrosine is ongoing to further understand its pharmacokinetic properties, therapeutic potential, and potential side effects. The compound has been synthesized through various chemical approaches, including fluorination reactions and modifications of tyrosine derivatives.'
| ID Source | ID |
|---|---|
| PubMed CID | 120656 |
| SCHEMBL ID | 296873 |
| MeSH ID | M0084285 |
| Synonym |
|---|
| 3,5-difluorotyrosine |
| tyrosine, 3,5-difluoro- |
| 369-96-0 |
| 2-amino-3-(3,5-difluoro-4-hydroxyphenyl)propanoic acid |
| 3,5-difluoro-dl-tyrosine |
| difluorotyrosine |
| SCHEMBL296873 |
| A903120 |
| DTXSID00958097 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||